Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 255

1.

Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy.

Feldman RJ, Christen WG, Ahmed AR.

Br J Dermatol. 2012 Mar;166(3):511-7. doi: 10.1111/j.1365-2133.2011.10658.x. Epub 2012 Jan 19.

PMID:
21967407
2.

Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.

Ahmed AR, Spigelman Z, Cavacini LA, Posner MR.

N Engl J Med. 2006 Oct 26;355(17):1772-9.

3.

Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris.

Behzad M, Möbs C, Kneisel A, Möller M, Hoyer J, Hertl M, Eming R.

Br J Dermatol. 2012 Apr;166(4):844-52. doi: 10.1111/j.1365-2133.2011.10732.x.

PMID:
22092243
4.

Low-dose rituximab is effective in pemphigus.

Horváth B, Huizinga J, Pas HH, Mulder AB, Jonkman MF.

Br J Dermatol. 2012 Feb;166(2):405-12. doi: 10.1111/j.1365-2133.2011.10663.x. Epub 2012 Jan 9.

PMID:
21967609
5.

Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up.

Reguiai Z, Tabary T, Maizières M, Bernard P.

J Am Acad Dermatol. 2012 Oct;67(4):623-9. doi: 10.1016/j.jaad.2011.12.019. Epub 2012 Jan 20.

PMID:
22261417
6.

Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus.

Czernik A, Beutner EH, Bystryn JC.

J Am Acad Dermatol. 2008 May;58(5):796-801. doi: 10.1016/j.jaad.2008.01.007.

PMID:
18423257
7.

Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab.

Pfütze M, Eming R, Kneisel A, Kuhlmann U, Hoyer J, Hertl M.

Dermatology. 2009;218(3):237-45. doi: 10.1159/000187431. Epub 2008 Dec 16.

PMID:
19088461
8.
9.

Response in patients with pemphigus vulgaris to rituximab therapy. Basis of the biology of B cells.

Leuci S, Levine D, Zhang J, Razzaque Ahmed A.

G Ital Dermatol Venereol. 2009 Aug;144(4):379-409. Review.

PMID:
19755943
10.

Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab).

Marzano AV, Fanoni D, Venegoni L, Berti E, Caputo R.

Dermatology. 2007;214(4):310-8.

PMID:
17460402
11.

Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption.

Eming R, Rech J, Barth S, Kalden JR, Schuler G, Harrer T, Hertl M.

Dermatology. 2006;212(2):177-87.

PMID:
16484825
12.

Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up.

Cianchini G, Lupi F, Masini C, Corona R, Puddu P, De Pità O.

J Am Acad Dermatol. 2012 Oct;67(4):617-22. doi: 10.1016/j.jaad.2011.11.007. Epub 2012 Jan 13.

PMID:
22243765
13.

A single cycle of rituximab for the treatment of severe pemphigus.

Joly P, Mouquet H, Roujeau JC, D'Incan M, Gilbert D, Jacquot S, Gougeon ML, Bedane C, Muller R, Dreno B, Doutre MS, Delaporte E, Pauwels C, Franck N, Caux F, Picard C, Tancrede-Bohin E, Bernard P, Tron F, Hertl M, Musette P.

N Engl J Med. 2007 Aug 9;357(6):545-52.

14.

Effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antidesmoglein 1 and antidesmoglein 3 antibodies in pemphigus vulgaris.

Green MG, Bystryn JC.

Arch Dermatol. 2008 Dec;144(12):1621-4. doi: 10.1001/archdermatol.2008.503.

PMID:
19075146
15.

[Intravenous immunoglobulin therapy: ELISA measurement of antidesmogleins 1 and 3 in three patients with pemphigus vulgaris].

Suárez-Fernández R, Longo I, Avilés JA, Bueno C, Rodríguez-Mahou M, Lázaro P.

Rev Clin Esp. 2006 Nov;206(10):499-503. Spanish.

PMID:
17129517
16.

Rituximab in pemphigus foliaceous with autoantibodies against both Desmoglein 1 and Desmoglein 3.

Carvalho R, Maio P, Cunha D, Freitas I, Afonso A, Cardoso J.

Eur J Dermatol. 2011 May-Jun;21(3):415-6. doi: 10.1684/ejd.2011.1288. No abstract available.

PMID:
21527367
18.

Evaluating efficacy of plasmapheresis for patients with pemphigus using desmoglein enzyme-linked immunosorbent assay.

Nagasaka T, Fujii Y, Ishida A, Handa M, Tanikawa A, Amagai M, Nishikawa T.

Br J Dermatol. 2008 Apr;158(4):685-90. doi: 10.1111/j.1365-2133.2007.08416.x. Epub 2008 Jan 30.

PMID:
18241273
19.

Desmoglein 1 and 3 enzyme-linked immunosorbent assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activity.

Daneshpazhooh M, Chams-Davatchi C, Khamesipour A, Mansoori P, Taheri A, Firooz A, Mortazavi H, Esmaili N, Dowlati Y.

J Eur Acad Dermatol Venereol. 2007 Nov;21(10):1319-24.

PMID:
17958835
20.

Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris.

Sami N, Qureshi A, Ruocco E, Ahmed AR.

Arch Dermatol. 2002 Sep;138(9):1158-62.

PMID:
12224976

Supplemental Content

Support Center